Updates & Impacts: Treating Heme Malignancies in 2022: CLL ASH Updates

Richard R. Furman, MD CLL Research Center



Weill Cornell Medical College

☐ NewYork-Presbyterian
☐ Weill Cornell Medical Center

Disclosures

- Research Funding: Acerta/AstraZeneca, Beigene, Janssen, TG Therapeutics
- Consultation: Abbvie, Acerta/AstraZeneca, Beigene, Genentech, Janssen, Loxo Oncology, Morphosys, Pharmacyclics, Sanofi, TG Therapeutics, Verastem, X4 Pharmaceuticals
- DSMB: Incyte

ASH 2021: Data for Review


- **1. CAPTIVATE**
- 2. GLOW
- 3. GAIA / CLL13

First-Line Treatment With Ibrutinib Plus Venetoclax for CLL: 2-Year Post-randomization Disease-Free Survival Results From the Minimal Residual Disease Cohort of the Phase 2 CAPTIVATE Study

Paolo Ghia, MD, PhD¹; John N. Allan, MD, PhD²; Tanya Siddiqi, MD³; Thomas J. Kipps, MD, PhD⁴; Bryone J. Kuss, MBBS, PhD, FRACP, FRCPA⁵; Stephen Opat, FRACP, FRCPA, MBBS⁶; Ian W. Flinn, MD, PhD⁷; Xavier C. Badoux, MBBS, FRACP, FRCPA⁸; Alessandra Tedeschi, MD⁹; Eva Gonzalez Barca, MD, PhD¹⁰; John M. Pagel, MD, PhD¹¹; Ryan Jacobs, MD¹²; Jacqueline C. Barrientos, MD, MS¹³; Edith Szafer-Glusman, PhD¹⁴; Cathy Zhou, MS¹⁴; Joi Ninomoto, PharmD¹⁴; James P. Dean, MD, PhD¹⁴; Constantine S. Tam, MBBS, MD¹⁵; William G. Wierda, MD, PhD¹⁶

Phase 2 CAPTIVATE Study


 CAPTIVATE (PCYC-1142) is an international, multicenter phase 2 study evaluating first-line treatment with 3 cycles of ibrutinib followed by 12 cycles of combined ibrutinib + venetoclax with 2 cohorts: MRD and FD



- Primary analyses of both cohorts have been previously reported^{1,2}
- Presented are updated results from the MRD cohort, with median time on study: 38.2 months (range, 15.0–47.9)
 - Median postrandomization follow-up: 24.0 months (range, 5.8–33.1)

1. Wierda WG et al. ASH 2020. Abstract #123. 2. Ghia P et al. ASCO 2021. Abstract #7501.


MRD Cohort: Patient Disposition and Randomization



^aIncludes 1 patient who discontinued venetoclax but completed planned treatment with ibrutinib. ^bDid not meet criteria for uMRD because of detectable MRD in PB and/or BM *or* undetectable MRD in PB that was not confirmed at consecutive assessments.

ASH 2021, CAPTIVATE-MRD; Ghia et al.


No New DFS Events Occurred Since Primary Analysis



- DFS was defined as freedom from MRD relapse (≥10⁻² confirmed on 2 separate occasions) and without PD or death starting from randomization after 15 cycles of treatment
- In the additional year of follow-up since the 1-year DFS primary analysis, no new MRD relapses,
 PD, or deaths occurred in patients with confirmed uMRD randomized to ibrutinib or placebo

ASH 2021, CAPTIVATE-MRD; Ghia et al.

Best uMRD Rates Improved With Further Treatment in uMRD Not Confirmed Population



- Greatest uMRD rate improvements occurred during the first year of randomized treatment
 - Greater improvements with ibrutinib + venetoclax than with ibrutinib
 - Suggests possible need for further therapy duration to maximize benefit
- Improvements in uMRD rates were similar between patients achieving CR or PR

Retreatment Data From the MRD Placebo Arm and FD Cohorts

- 12 patients progressed after FD treatment^a with ibrutinib + venetoclax retreated with single-agent ibrutinib
 - Median follow-up on retreatment: 4.9 months (range, 0.0–27.6)
 - Of 9 patients with available response, all have PR; 3 patients have pending responses
 - 8 of 9 had high-risk features

Patient	Cohort	Baseline high-risk features			Response to fixed-duration lbr + Ven		
		del(17p)	<i>TP53</i> mutated	Unmutated IGHV	Complex karyotype	PFS (months)	Best response
1	FD	No	No	Yes	No	36.5	CR
2	FD	No	No	Yes	Yes	27.6	CR
3	FD	Yes	No	No	No	28.5	CRi
4	FD	No	No	No	Yes	30.4	PR
5	FD	No	No	No	No	27.4	PR
6	FD	No	No	No	Yes	22.0	PR
7	MRD-placebo	No	No	Yes	No	20.3	PR
8	MRD-placebo	No	No	Yes	No	19.4	PR
9	FD	Yes	No	Yes	Yes	16.6	PR

Summary

- With an additional year of follow-up since the primary analysis, there were no new MRD relapses, PD, or deaths in patients with confirmed uMRD treated with placebo or ibrutinib
 - The 2-year DFS rate with fixed-duration treatment (randomized to placebo) was maintained at 95%
- Early data suggest that patients who progress after fixed-duration treatment with ibrutinib + venetoclax can be successfully retreated with single-agent ibrutinib; <u>but much</u> <u>more data is required!</u>
- With median study follow-up of 38 months, AEs remained consistent with known profiles for single-agent ibrutinib and venetoclax; no new safety signals emerged

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The GLOW Study

Talha Munir,¹ Carol Moreno,² Carolyn Owen,³ George Follows,⁴ Ohad Benjamini,⁵ Ann Janssens,⁶ Mark-David Levin,⁷ Anders Osterborg,⁸ Tadeusz Robak,⁹ Martin Simkovic,¹⁰ Don Stevens,¹¹ Sergey Voloshin,¹² Vladimir Vorobyev,¹³ Munci Yagci,¹⁴ Loic Ysebaert,¹⁵ Qianya Qi,¹⁶ Andrew J. Steele,¹⁷ Natasha Schuier,¹⁸ Kurt Baeten,¹⁹ Donne Bennett Caces,¹⁶ Carsten U. Niemann,²⁰ Arnon P. Kater²¹

¹St James's Hospital, Leeds, UK; ²Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain; ³Tom Baker Cancer Centre, Calgary, Canada; ⁴Addenbrookes Hospital, Cambridge, UK; ³Sheba Medical Center, Ramat Gan, Israel; ⁶UZ Leuven Gasthuisberg, Leuven, Belgium; ⁷Albert Schweitzer Hospital, Dordrecht, Netherlands; ⁸Karolinska University Hospital, Stockholm, Sweden; ⁹Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland; ¹⁰University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; ¹¹Norton Cancer Institute, Louisville, KY, USA; ¹²Russian Scientific and Research Institute of Hematology and Transfusiology, St. Petersburg, Russia; ¹³S.P. Botkin Moscow City Clinical Hospital, Moscow, Russia; ¹⁴Gazi Universitesi Tip Fakultesi, Ankara, Turkey; ¹³Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France; ¹⁶Janssen Research & Development, Raritan, NJ, USA; ¹⁷Janssen Research & Development, Spring House, PA, USA; ¹⁸Janssen Research & Development, Düsseldorf, Germany; ¹⁹Janssen Research & Development, Beerse, Belgium; ²⁰Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; ²¹Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Netherlands

GLOW: Ibrutinib + Venetoclax vs Obinutuzumab + Chlorambucil

Eligibility criteria:


- Untreated CLL
- Aged ≥65 yr or <65 yr with CIRS
 >6 or CrCl <70 mL/min
- No del(17p) or TP53 mutation
- ECOG PS 0-2

Ibrutinib 420 mg PO QD x 3 cycles, Ibrutinib + Venetoclax 12 cycles (n = 106)


Chlorambucil 0.5 mg/kg on D1, 15 + Obinutuzumab 1000 mg x 6 cycles (n = 105) If IRC-confirmed PD and active disease → requiring tx, eligible for single-agent ibrutinib

- Primary endpoint: PFS per IRC
 - 71 PFS events to detect effect size with HR of 0.5 (80% power, 2-sided α = 0.05)
- Key secondary endpoints: uMRD in BM, CR rate per IRC, ORR per IRC, OS, safety

GLOW: Progression-Free Survival



GLOW: uMRD at EOT+3



- Rate of uMRD was significantly higher with Ibr+Ven vs Clb+O in BM and PB
- uMRD concordance in PB/BM: 92.9% for Ibr+Ven vs 43.6% for Clb+O

Munir T. abstract 70, ASH 2021.

uMRD PB Rates: EOT+3 to EOT+12

EOT +3 EOT +12 EOT +3 EOT +12 1 (0.9%) 17 (16.2%) 21 (19.8%) 6 (5.7%) 8 (7.5%) 50 (47,6%) 24 (22.6%) 22 (20,8%) 37 (35.2%) 12 (11.3%) 17 (16.2%) 13 (12.3%) 22 (21.0%) 22 (21.0%) 46 (43.4%) 39 (36.8%) 6 (5.7%) 19 (18.0%) 7 (6.7%) MRD < 10⁻⁵ MRD ≥ 10⁻⁵ to < 10⁻⁴ MRD ≥ 10⁻⁴ to < 10⁻² MRD ≥ 10⁻² NR/Death/PD Missing

Ibr+Ven


Clb+O

Sustained uMRD seen in: Ibr+Ven: 80.4% Clb+O: 29.3%

uMRD rate EOT+3 to EOT+12 Ibr+Ven: decrease 6% Clb+O: decrease 27%

Munir T. abstract 70, ASH 2021.

PFS Based on BM uMRD Status at EOT+3



- PFS rate during first year post-EOT sustained at >90% in Ibr+Ven, independent of BM MRD status
- Rapid relapse in non-uMRD patients treated with Clb+O

Munir T. abstract 70, ASH 2021.

Summary

- Ibr+Ven achieved deeper and better sustained uMRD compared with Clb+O
- Molecular and clinical relapses less frequent with Ibr+Ven
- Patients not attaining uMRD on Ibr+Ven still had PFS > 90% at 1 year
- Correlation between MRD status and PFS important predictor in era of novel agents
 - Lymphocytosis
 - Persistent LAD/organomegaly

A RANDOMIZED PHASE III STUDY OF

VENETOCLAX-BASED TIME-LIMITED COMBINATION TREATMENTS (RVE, GVE, GIVE) VS STANDARD CHEMOIMMUNOTHERAPY (CIT: FCR/BR) IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA OF FIT PATIENTS: FIRST CO-PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL INTERGROUP GAIA (CLL13) TRIAL


Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christoph Schneider, Christian Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Use Christiansen, Thomas Nösslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jäger, Henrik Frederiksen, Maria BL Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Florian Simon, Nisha De Silva, Anna Fink, Kirsten Fischer, Clemens Wendtner, Karl A Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Eichhorst B. ASH 2021 abstract 71.

Comparison of time limited therapies in frontline of CLL: Are venetoclax-based, time limited therapies superior to BR/FCR ?


CLL14 Study of the GCLLSG in less fit patients

CLL10 Study of the GCLLSG in **fit** patients




GAIA/CLL13 Study : Design

Chemoimmunotherapy (FCR/BR) versus Rituximab + Venetoclax versus Obinutuzumab (G) + Ve versus G + Ibrutinib + Ve




GAIA/CLL13 Study : Treatment regimen

Treatment regimen in 28 days (D) interval cycles (C)



GAIA/CLL13 Study : Flow diagram

Eudract 2015-004936-36; NCT 02950051



* 13 pts did not receive treatment


Treatment exposure

Median FU 27.9 months (range: 0.0 – 49.0)

	СІТ	RVe	GVe	GIVe
Planned number of cycles	6	12	12	12-36
All patients of safety population	216	237	228	231
Pts completed treatment (%)	176 (81.5%)	219 (92.4 %)	214 (93.9%)	197 (85.3%)*
Reason for discontinuation ⁺				
AEs or intercurrent illness	33	14	13	28
Progressive disease	2	4	3	0
Other	9	6	3	6
Reduced dose intensity (%)	32 (14.8%)	44 (19.3%)	47 (21.5%)	81 (36.5%)


 *In GIVe arm: Pts with at least 12 cycles were considered as completed treatment: (ibrutinib alone beyond cycle 12) Therapy received: 12 cycles (35, 19%), 13-15 cycles (135, 72%), 16-36 cycles (18, 10%)
 *Early treatment discontinuations might be caused by more than one reason

Coprimary endpoint: uMRD (< 10⁻⁴) at Mo15 in PB by 4-colour-flow



proportion of ITT population in %

PB MRD rates by NGS at Mo15



Adverse Events > Grade 3

Severe AEs occurring in **>**5% of patients and AEs of interest

	СІТ	Rve	Gve	GIVe
All patients	216	237	228	231
Anemia	16 (7.4)	9 (3.8)	11 (4.8)	9 (3.9)
Neutropenia	113 (52.3)	109 (46.0)	127 (55.7)	112 (48.5)
Thrombocytopenia	22 (10.2)	10 (4.2)	7 (3.1)	18 (7.8)
Febrile Neutropenia	24 (11.1)	10 (4.2)	7 (3.1)	18 (7.8)
Infections	43 (19.9)	27 (11.4)	32 (14.0)	51 (22.1)
TLS	9 (4.2)	24 (10.1)	20 (8.8)	15 (6.5)
Bleeding	1 (0.5)	1 (0.4)	1 (0.4)	4 (1.7)
Atrial Fibrillation	1 (0.5)	1 (0.4)	0 (0.0)	6 (2.6)

Adverse Events > Grade 3

Severe AEs occurring in **>**5% of patients and AEs of interest

	СІТ	Rve	Gve	GIVe
All patients	216	237	228	231
Anemia	16 (7.4)	9 (3.8)	11 (4.8)	9 (3.9)
Neutropenia	113 (52.3)	109 (46.0)	127 (55.7)	112 (48.5)
Thrombocytopenia	22 (10.2)	10 (4.2)	7 (3.1)	18 (7.8)
Febrile Neutropenia	24 (11.1)	10 (4.2)	7 (3.1)	18 (7.8)
Infections	43 (19.9)	27 (11.4)	32 (14.0)	51 (22.1)
TLS	9 (4.2)	24 (10.1)	20 (8.8)	15 (6.5)
Bleeding	1 (0.5)	1 (0.4)	1 (0.4)	4 (1.7)
Atrial Fibrillation	1 (0.5)	1 (0.4)	0 (0.0)	6 (2.6)

Summary

- GVe-based regimens superior to CIT in achieving uMRD in fit patients
 - GVe vs CIT: 86.5% vs 52.0%
 - GIVe vs CIT: 92.2% vs 52.0%
- RVe not superior to CIT in achieving uMRD: 57.0% vs 52.0%
- PFS
- GVe exceeded CLL14
 - GAIA excluded deletion 17p
 - Better treatment adherence with fit patients (CLL14: 70%; GAIA: 93.9%)
- GVe comparable to GIVe
 - uMRD rates not statistically compared; will be for PFS
 - uMRD measured at month 15; GVe 12 months vs GIVe longer if not uMRD